BioStem Tech

Q2 FY2026 EarningsQ2 FY26 results beat revenue expectations but missed significantly on GAAP earnings, with a net loss of $8.97M compared to a projected $8.57M loss. Revenue of $7.90M exceeded the $6.35M consensus, primarily driven by the integration of BioTissue assets which contributed $6.71M in hospital sales. However, adjusted EPS of -$0.52 missed the $0.05 normalized expectation due to a 346% YoY surge in COGS and increased sales commissions following the acquisition. Management highlighted substantial doubt regarding the company's ability to continue as a going concern due to upcoming $10M FDA-related contingent payments and reduced Medicare reimbursement rates.